Vita 34 AG
XETRA:V3V

Watchlist Manager
Vita 34 AG Logo
Vita 34 AG
XETRA:V3V
Watchlist
Price: 4.06 EUR -0.98% Market Closed
Market Cap: 71.6m EUR
Have any thoughts about
Vita 34 AG?
Write Note

Vita 34 AG
Investor Relations

Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Jakub Julian Baran
Chairman of the Management Board & CEO
No Bio Available
Mr. Tomasz Franciszek Baran
Vice President of the Management Board & Chief Commercial Officer
No Bio Available
Thomas Pfaadt
Chief Financial Officer
No Bio Available
Santiago Luengo
Managing Director of Secuvita
No Bio Available

Contacts

Address
SACHSEN
Leipzig
Deutscher Platz 5a
Contacts
+49341487920.0
www.vita34.de